areta has a consolidated ten-year experience in the field of cell culture and biologicals for clinical, preclinical and R&D studies. The strong commitment towards quality, the multipurpose production facility and the GMP authorization provided by AIFA [Italian Medicines Agency], in compliance with EU requirements, to manufacture and release drug batches for clinical trials, make areta the reliable partner for the development of innovative therapies.
The business model of areta is based on R&D and GMP contract manufacturing. Since its foundation, areta has been investing an important part of its budget in human resources and funded research projects (EU-funded or national), acquiring a deep and updated know-how and being always in contact with the most innovative technologies in the field. The interaction between different expertises makes areta extremely flexible and versatile in the management of customized research and development projects.
The expansion strategy of areta is based on the concept of “cloning” the company, through small, focused and high-quality units that constitute new centers of excellence in the selected therapeutic field or product of interest.